Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer
Launched by NRG ONCOLOGY · Sep 17, 2021
Trial Information
Current as of July 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different ways of using a chemotherapy drug called cisplatin along with radiation therapy to treat patients with advanced head and neck cancer. The researchers want to find out if giving a lower dose of cisplatin weekly is just as effective or even better than giving a higher dose every three weeks when combined with radiation treatment. Cisplatin works to kill cancer cells or stop them from growing, while radiation uses high-energy X-rays to target and shrink tumors.
To be eligible for this trial, participants must be at least 18 years old and diagnosed with specific types of advanced head and neck cancers, including oropharyngeal or laryngeal cancers. They should have measurable disease and meet certain health criteria, such as having a good performance status and specific blood test results. Participants can expect to receive either treatment regimen while being closely monitored for their health and response to therapy. It’s important to note that this trial is currently recruiting patients, so there is an opportunity to participate if they meet the eligibility criteria.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Pathologically (histologically or cytologically) proven diagnosis of SCCHN of the oropharynx, larynx, hypopharynx, or p16-positive unknown primary prior to registration; specimen from cervical lymph nodes with a well-defined primary site documented clinically or radiologically is acceptable; in patients with carcinoma of unknown primary this will be sufficient for pathologic confirmation without a clinically or radiographically defined primary site
- * For patients with oropharyngeal cancer (OPC)/cancer of unknown primary (CUP):
- • P16 status based on local site immunohistochemical tissue staining is required. A cell block obtained from a fine needle aspiration (FNA) biopsy specimen may be used as the sole diagnostic tissue. Centers are encouraged to contact the pathology chair for clarification.
- • Note: Institutions must screen patients for p16 status by immunohistochemistry (IHC) in order to be eligible for the trial using a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory. A rigorous laboratory accreditation process similar to the United States (U.S.) CLIA certification, such as the provincial accreditation status offered by the Ontario Laboratory Accreditation (OLA) Program in Canada, the College of American Pathologists (CAP), or an equivalent accreditation in other countries, is acceptable.
- • The p16 results must be reported on the pathology report being submitted. The p16 positivity is defined as \> 70% of tumor cells showing strong nuclear and/or cytoplasmic immunostaining with p16 antibody.
- • For patients with laryngeal and hypopharyngeal primaries: Analysis of p16 status is NOT required.
- • Patients must have clinically or radiographically evident measurable disease at the primary site or at nodal stations. Simple tonsillectomy or local excision of the primary without removal of nodal disease is permitted, as is excision removing gross nodal disease but with intact primary site. Limited neck dissections retrieving =\< 4 nodes are permitted and considered as non-therapeutic nodal excisions
- * Clinical stage (American Joint Committee on Cancer \[AJCC\], 8th ed.), including no distant metastases based on the following diagnostic workup:
- • History/physical examination within 60 days prior to registration
- * One of the following imaging studies is required within 60 days prior to registration:
- • Computed tomography (CT) scan of neck (diagnostic quality with contrast, unless contraindicated) OR
- • Magnetic resonance imaging (MRI) of the neck (diagnostic quality with contrast, unless contraindicated) OR
- • Fludeoxyglucose F-18 (FDG)-positron emission tomography (PET)/CT of the neck; the CT component must be of diagnostic quality with contrast, unless contraindicated.
- • Note: A diagnostic quality CT or MRI with contrast or FDG-PET/CT scan of neck performed for the purposes of radiation planning may serve as both staging and planning tools
- * One of the following imaging studies is required within 60 days prior to registration:
- • FDG-PET/CT of the chest; FDG-PET/CT scan is strongly preferred and highly recommended to be used for eligibility OR
- • Chest CT
- • Exam with laryngopharyngoscopy (mirror or in office direct procedure acceptable) within 70 days prior to registration;
- • Eligibility by patient cohort;
- • Non-OPC/p16-negative OPC Cohort; Tumor Site: Larynx/Hypopharynx; Clinical Staging (AJCC, 8th ed.): T3-4 N0 or T1-4 N1-3 T2 N0 (hypopharynx only)
- • Tumor Site: p16-negative OPC; Clinical Staging (AJCC, 8th ed.): T2N1, T1-4 N2-3, or T3-4 N0-1
- • p16-positive OPC/CUP Cohort;
- • Tumor Site: OPC; Smoking Status: =\< 10 pack-years; Clinical Staging (AJCC, 8th ed.): T1-3 N2-3 or T4 N0-3
- • Tumor Site: OPC; Smoking Status: \> 10 pack-years; Clinical Staging (AJCC, 8th ed.): T1N2-3, T2N1-3, or T3-4 N0-3
- • Tumor Site: CUP; Smoking Status: Any; Clinical Staging (AJCC, 8th ed.): T0 N2-3 Note: Cigar and pipe tobacco consumption is not included in calculating the lifetime pack-years. Marijuana consumption is likewise not considered in this calculation. There is also no clear scientific evidence regarding the role of chewing tobacco-containing products in oropharyngeal cancer, although this is possibly more concerning given the proximity of the oral cavity and oropharynx. In any case, investigators should not count use of non-cigarette tobacco products in the pack-years calculation.
- • Age \>= 18
- • Zubrod (Eastern Cooperative Oncology Group \[ECOG\]) performance status of 0-1 within 14 days prior to registration
- • Absolute neutrophil count (ANC) \>= 1,500 cells/mm\^3 (within 30 days prior to registration)
- • Platelets \>= 75,000 cells/mm\^3 (within 30 days prior to registration)
- • Hemoglobin \>= 8.0 g/dL (within 30 days prior to registration)
- • Note: The use of transfusion or other intervention to achieve hemoglobin \[Hgb\] \>= 8.0 g/dL is acceptable)
- • Calculated creatinine clearance (CrCl) \>= 50 mL/min by the Cockcroft-Gault formula (within 30 days prior to registration)
- • Total bilirubin =\< 1.5 x institutional upper limit of normal (ULN) (within 30 days prior to registration) (not applicable to patients with known Gilbert's syndrome)
- • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 1.5 x institutional ULN (within 30 days prior to registration)
- • Known human immunodeficiency virus (HIV) infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months and CD4 T Cell count \> 200 cells/mm\^3 are eligible for this trial. Testing is not required for entry into protocol
- • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
- • Negative urine or serum pregnancy test (in persons of childbearing potential) within 14 days prior to registration. Childbearing potential is defined as any person who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes
- • Willing to use highly effective contraceptives for participants of childbearing potential (participants who may become pregnant or who may impregnate a partner) during therapy and for 14 months (females); for 11 months (males) following last dose of cisplatin; this inclusion is necessary because the treatment in this study may be significantly teratogenic.
- • The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information
- Exclusion Criteria:
- • Patients with oral cavity cancer, nasopharynx cancer, or p16-negative cancer of unknown primary (CUP)
- • Recurrence of the study cancer
- • Definitive clinical or radiologic evidence of distant metastatic disease
- • Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable, however, any prior exposure to cisplatin is excluded
- • Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
- * Severe, active co-morbidity defined as follows:
- • Unstable angina requiring hospitalization in the last 6 months
- • Myocardial infarction within the last 6 months
- • New York Heart Association Functional Classification III/IV (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification.)
- • Persistent grade 3-4 (CTCAE version 5.0) electrolyte abnormalities that cannot be reversed despite replacement as indicated by repeat testing
- • Patient must not have an active infection requiring IV antibiotics prior to registration;
- • Other chronic renal disease like nephrotic syndrome, that could be worsened by cisplatin therapy
- • History of allogenic organ transplantation
- • Any symptomatic peripheral sensory neuropathy grade \>= 2 (CTCAE version 5.0);
- • Pregnancy and individuals unwilling to discontinue nursing
- • History of hypersensitivity to cisplatin or platinum-containing compounds
About Nrg Oncology
NRG Oncology is a prominent clinical trial sponsor dedicated to advancing cancer research through innovative multi-institutional studies. Comprising a collaborative network of leading academic institutions and community hospitals, NRG Oncology focuses on enhancing patient outcomes by conducting rigorous clinical trials that evaluate new treatment strategies and improve existing therapies. With a commitment to scientific excellence and patient-centered care, the organization plays a vital role in shaping the future of oncology by integrating cutting-edge research with clinical practice, ultimately striving to translate findings into meaningful improvements in cancer care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lebanon, New Hampshire, United States
Cleveland, Ohio, United States
Milwaukee, Wisconsin, United States
Charleston, South Carolina, United States
Cleveland, Ohio, United States
Buffalo, New York, United States
Seattle, Washington, United States
Washington, District Of Columbia, United States
Philadelphia, Pennsylvania, United States
Flint, Michigan, United States
Denver, Colorado, United States
Flint, Michigan, United States
Sioux Falls, South Dakota, United States
Maywood, Illinois, United States
Peoria, Illinois, United States
Detroit, Michigan, United States
Salt Lake City, Utah, United States
Saskatoon, Saskatchewan, Canada
Regina, Saskatchewan, Canada
Little Rock, Arkansas, United States
Oklahoma City, Oklahoma, United States
Des Moines, Iowa, United States
La Crosse, Wisconsin, United States
Cleveland, Ohio, United States
Ann Arbor, Michigan, United States
Jackson, Mississippi, United States
Logan, Utah, United States
Ogden, Utah, United States
Salina, Kansas, United States
Bryn Mawr, Pennsylvania, United States
Urbana, Illinois, United States
Ann Arbor, Michigan, United States
Mobile, Alabama, United States
Dayton, Ohio, United States
Effingham, Illinois, United States
Johnson Creek, Wisconsin, United States
Springfield, Illinois, United States
Philadelphia, Pennsylvania, United States
Houston, Texas, United States
Fairfax, Virginia, United States
Roseville, California, United States
Springfield, Illinois, United States
Media, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Tampa, Florida, United States
Rochester, New York, United States
Houston, Texas, United States
Salt Lake City, Utah, United States
Modesto, California, United States
Orange, California, United States
Palo Alto, California, United States
Sacramento, California, United States
San Francisco, California, United States
Washington, District Of Columbia, United States
Baltimore, Maryland, United States
Southfield, Michigan, United States
Saint Cloud, Minnesota, United States
Saint Louis, Missouri, United States
Omaha, Nebraska, United States
Winston Salem, North Carolina, United States
Bismarck, North Dakota, United States
Fargo, North Dakota, United States
Columbus, Ohio, United States
Hershey, Pennsylvania, United States
Wynnewood, Pennsylvania, United States
Aurora, Illinois, United States
Lexington, Kentucky, United States
Cleveland, Ohio, United States
Kettering, Ohio, United States
Mayfield Heights, Ohio, United States
Provo, Utah, United States
Cape Girardeau, Missouri, United States
Elmhurst, Illinois, United States
New Orleans, Louisiana, United States
Memphis, Tennessee, United States
Beverly Hills, California, United States
Glens Falls, New York, United States
Louisville, Kentucky, United States
Oakland, California, United States
Miami, Florida, United States
Albuquerque, New Mexico, United States
Stony Brook, New York, United States
Sioux Falls, South Dakota, United States
Houston, Texas, United States
Sacramento, California, United States
San Francisco, California, United States
Augusta, Georgia, United States
Detroit, Michigan, United States
Saint Louis, Missouri, United States
Toledo, Ohio, United States
Madison, Wisconsin, United States
Marshfield, Wisconsin, United States
Palo Alto, California, United States
Decatur, Illinois, United States
Ottawa, Illinois, United States
Peoria, Illinois, United States
Butte, Montana, United States
Clive, Iowa, United States
Des Moines, Iowa, United States
Des Moines, Iowa, United States
Des Moines, Iowa, United States
Jackson, Michigan, United States
Warren, Michigan, United States
Rochester, New York, United States
Seattle, Washington, United States
Los Angeles, California, United States
Des Moines, Iowa, United States
Livonia, Michigan, United States
Pontiac, Michigan, United States
Sandusky, Ohio, United States
Paoli, Pennsylvania, United States
Alexandria, Virginia, United States
Rohnert Park, California, United States
Sacramento, California, United States
Fremont, California, United States
Los Angeles, California, United States
Richmond, California, United States
Roseville, California, United States
Sacramento, California, United States
San Francisco, California, United States
San Jose, California, United States
San Leandro, California, United States
Santa Clara, California, United States
Santa Rosa, California, United States
South San Francisco, California, United States
Stockton, California, United States
Vallejo, California, United States
Walnut Creek, California, United States
Galesburg, Illinois, United States
Kansas City, Kansas, United States
Topeka, Kansas, United States
New Orleans, Louisiana, United States
Portland, Maine, United States
Bemidji, Minnesota, United States
Joplin, Missouri, United States
Springfield, Missouri, United States
Springfield, Missouri, United States
Pinehurst, North Carolina, United States
Akron, Ohio, United States
Dayton, Ohio, United States
Franklin, Ohio, United States
Mentor, Ohio, United States
Sylvania, Ohio, United States
Troy, Ohio, United States
Sioux Falls, South Dakota, United States
American Fork, Utah, United States
Cedar City, Utah, United States
Murray, Utah, United States
Salt Lake City, Utah, United States
Seattle, Washington, United States
Minocqua, Wisconsin, United States
Oconomowoc, Wisconsin, United States
Rhinelander, Wisconsin, United States
Rice Lake, Wisconsin, United States
Stevens Point, Wisconsin, United States
Weston, Wisconsin, United States
Berkeley, California, United States
Mountain View, California, United States
Palo Alto, California, United States
Denver, Colorado, United States
Chicago, Illinois, United States
Naperville, Illinois, United States
Wooster, Ohio, United States
Antigo, Wisconsin, United States
Wausau, Wisconsin, United States
Ottawa, Ontario, Canada
Livonia, Michigan, United States
Toronto, Ontario, Canada
Littleton, Colorado, United States
Albuquerque, New Mexico, United States
Charleston, West Virginia, United States
Marysville, California, United States
Louisville, Kentucky, United States
Houston, Texas, United States
Canton, Illinois, United States
Carthage, Illinois, United States
Eureka, Illinois, United States
Kewanee, Illinois, United States
Macomb, Illinois, United States
Peru, Illinois, United States
Princeton, Illinois, United States
Hines, Illinois, United States
Rockford, Illinois, United States
Parker, Colorado, United States
La Jolla, California, United States
San Diego, California, United States
Truckee, California, United States
Bloomington, Illinois, United States
Pekin, Illinois, United States
Scarborough, Maine, United States
Barberton, Ohio, United States
Greenwood, South Carolina, United States
Saint George, Utah, United States
Wisconsin Rapids, Wisconsin, United States
Auburn, California, United States
Carmichael, California, United States
Roseville, California, United States
Saint Johnsbury, Vermont, United States
Santa Rosa, California, United States
Vacaville, California, United States
Denver, Colorado, United States
Lafayette, Colorado, United States
Olathe, Kansas, United States
Jefferson City, Missouri, United States
Erie, Pennsylvania, United States
Montreal, Quebec, Canada
Galway, Co Galway, Ireland
Dearborn, Michigan, United States
Jonesboro, Arkansas, United States
Anaheim, California, United States
Antioch, California, United States
Bellflower, California, United States
Fresno, California, United States
Irvine, California, United States
Modesto, California, United States
Oakland, California, United States
Rancho Cordova, California, United States
Roseville, California, United States
South San Francisco, California, United States
Sunnyvale, California, United States
West Des Moines, Iowa, United States
Overland Park, Kansas, United States
Bel Air, Maryland, United States
Kansas City, Missouri, United States
Lee's Summit, Missouri, United States
Rolla, Missouri, United States
Rolla, Missouri, United States
Fargo, North Dakota, United States
Strongsville, Ohio, United States
Monroeville, Pennsylvania, United States
Kirkland, Washington, United States
Urbana, Illinois, United States
Springfield, Illinois, United States
Aarau, , Switzerland
Chai Wan, , Hong Kong
Fairfax, Virginia, United States
Great Falls, Montana, United States
Auburn, California, United States
Clive, Iowa, United States
West Des Moines, Iowa, United States
Brighton, Michigan, United States
Brighton, Michigan, United States
Canton, Michigan, United States
Canton, Michigan, United States
Chelsea, Michigan, United States
Chelsea, Michigan, United States
Pontiac, Michigan, United States
Ypsilanti, Michigan, United States
Centerville, Ohio, United States
Houston, Texas, United States
Sugar Land, Texas, United States
Bay Pines, Florida, United States
Creston, Iowa, United States
Lexington, Kentucky, United States
Lexington, Kentucky, United States
Centralia, Illinois, United States
Danville, Illinois, United States
Decatur, Illinois, United States
Effingham, Illinois, United States
Mattoon, Illinois, United States
O'fallon, Illinois, United States
Louisville, Kentucky, United States
Brighton, Michigan, United States
Brownstown, Michigan, United States
Canton, Michigan, United States
Chelsea, Michigan, United States
Clinton Township, Michigan, United States
Novi, Michigan, United States
West Bloomfield, Michigan, United States
Ypsilanti, Michigan, United States
Sainte Genevieve, Missouri, United States
Sullivan, Missouri, United States
Sunset Hills, Missouri, United States
Centerville, Ohio, United States
Dayton, Ohio, United States
Franklin, Ohio, United States
Lone Tree, Colorado, United States
Gulfport, Mississippi, United States
Dublin, California, United States
Fresno, California, United States
Sacramento, California, United States
San Rafael, California, United States
Novi, Michigan, United States
Monticello, Minnesota, United States
Columbus, Mississippi, United States
Grenada, Mississippi, United States
New Albany, Mississippi, United States
Oxford, Mississippi, United States
Southhaven, Mississippi, United States
Mansfield, Ohio, United States
Medina, Ohio, United States
Ravenna, Ohio, United States
Riverton, Utah, United States
Eau Claire, Wisconsin, United States
Milwaukee, Wisconsin, United States
Fremont, California, United States
Wexford, Pennsylvania, United States
Menomonee Falls, Wisconsin, United States
Mukwonago, Wisconsin, United States
West Bend, Wisconsin, United States
Waukesha, Wisconsin, United States
Ontario, California, United States
Des Moines, Iowa, United States
Westwood, Kansas, United States
South Portland, Maine, United States
Columbia, Maryland, United States
Coral Gables, Florida, United States
Deerfield Beach, Florida, United States
Glen Burnie, Maryland, United States
North Kansas City, Missouri, United States
Jefferson Hills, Pennsylvania, United States
Costa Mesa, California, United States
Elk Grove, California, United States
Rocklin, California, United States
Sacramento, California, United States
Woodland, California, United States
Bath, Maine, United States
Sanford, Maine, United States
Brewer, Maine, United States
Miami, Florida, United States
Baltimore, Maryland, United States
Beavercreek, Ohio, United States
Stevens Point, Wisconsin, United States
Los Angeles, California, United States
Clarkston, Michigan, United States
Farmington Hills, Michigan, United States
Troy, Michigan, United States
Collierville, Tennessee, United States
Plantation, Florida, United States
Bellevue, Nebraska, United States
Omaha, Nebraska, United States
Biddeford, Maine, United States
Sanford, Maine, United States
Brighton, Michigan, United States
Oak Creek, Wisconsin, United States
Tampa, Florida, United States
San Jose, California, United States
Madison, Wisconsin, United States
Dublin, Co Dublin, Ireland
Washington, Illinois, United States
Farmington, Missouri, United States
Redwood City, California, United States
Colorado Springs, Colorado, United States
Tampa, Florida, United States
Wilmington, North Carolina, United States
Aventura, Florida, United States
Bozeman, Montana, United States
Golden, Colorado, United States
Carmichael, California, United States
Baytown, Texas, United States
Houston, Texas, United States
Nassau Bay, Texas, United States
The Woodlands, Texas, United States
Wilkesboro, North Carolina, United States
Macomb, Michigan, United States
Madison Heights, Michigan, United States
Springfield, Illinois, United States
Lexington, Kentucky, United States
Wesley Chapel, Florida, United States
Wilmington, North Carolina, United States
Seattle, Washington, United States
Seattle, Washington, United States
Avon, Ohio, United States
Bellevue, Washington, United States
Des Moines, Iowa, United States
Encinitas, California, United States
Supply, North Carolina, United States
Lebanon, New Hampshire, United States
Pontiac, Michigan, United States
Ann Arbor, Michigan, United States
Brighton, Michigan, United States
Chelsea, Michigan, United States
Dayton, Ohio, United States
Webster, New York, United States
Danville, Illinois, United States
Greenville, Ohio, United States
Canton, Michigan, United States
Rhinelander, Wisconsin, United States
Stevens Point, Wisconsin, United States
Minocqua, Wisconsin, United States
Clarkston, Michigan, United States
Farmington Hills, Michigan, United States
Madison Heights, Michigan, United States
Macomb, Michigan, United States
Ankeny, Iowa, United States
Sunset Hills, Missouri, United States
Bay Pines, Florida, United States
O'fallon, Illinois, United States
Des Moines, Iowa, United States
Clive, Iowa, United States
Carmichael, California, United States
Rockford, Illinois, United States
Jefferson City, Missouri, United States
Pontiac, Michigan, United States
Madison, Wisconsin, United States
Kirkland, Washington, United States
Saint Johnsbury, Vermont, United States
Dayton, Ohio, United States
Dayton, Ohio, United States
Troy, Michigan, United States
Johnson Creek, Wisconsin, United States
Irvine, California, United States
Golden, Colorado, United States
Southfield, Michigan, United States
Novi, Michigan, United States
Madison, Wisconsin, United States
Detroit, Michigan, United States
Warren, Michigan, United States
Havre, Montana, United States
Denver, Colorado, United States
Olathe, Kansas, United States
Ankeny, Iowa, United States
Clive, Iowa, United States
Des Moines, Iowa, United States
Des Moines, Iowa, United States
Denver, Colorado, United States
Waukee, Iowa, United States
Rolla, Missouri, United States
Littleton, Colorado, United States
Parker, Colorado, United States
Biddeford, Maine, United States
Sanford, Maine, United States
South Portland, Maine, United States
Portland, Maine, United States
Scarborough, Maine, United States
Patients applied
Trial Officials
Paul M Harari
Principal Investigator
NRG Oncology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials